• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Brian Orelli

Brian Orelli

Articles

ARTICLES

Going after new PARP targets, Ribon lands $65M series C round to target monoPARPs

Jan. 4, 2019
By Brian Orelli

Coming out of stealth mode, Ribon Therapeutics Inc. secured a $65 million series B financing round, adding to the $43 million series A the company raised in November 2015, to advance its pipeline of drugs targeting monoPARPs, a subset of 12 members of the poly ADP-ribose polymerase (PARP) family.


Read More

Multiple platforms look to attack hard-to-drug targets

Dec. 20, 2018
By Brian Orelli
There are many proteins in humans, bacteria and viruses that would make great targets to shut down a pathway to treat a disease or stop an infection, but, for a variety of reasons, designing drugs to target those proteins has been difficult.
Read More

An inflection point for ATTR: Approvals, data and more

Dec. 19, 2018
By Brian Orelli
Transthyretin (TTR) amyloidosis (ATTR), a rare disease caused by the misfolding and aggregation of the TTR protein, has reached an inflection point with two drugs approved to treat the disease this year and multiple drugs in development.
Read More

Multiple platforms look to attack hard-to-drug targets

Dec. 17, 2018
By Brian Orelli
There are many proteins in humans, bacteria and viruses that would make great targets to shut down a pathway to treat a disease or stop an infection, but, for a variety of reasons, designing drugs to target those proteins has been difficult.
Read More

An inflection point for ATTR: approvals, data and more

Dec. 10, 2018
By Brian Orelli
Transthyretin (TTR) amyloidosis (ATTR), a rare disease caused by the misfolding and aggregation of the TTR protein, has reached an inflection point with two drugs approved to treat the disease this year and multiple drugs in development.
Read More

Imbruvica moving into first-line CLL across spectrum of patients

Dec. 4, 2018
By Brian Orelli
SAN DIEGO – Imbruvica (ibrutinib) was first approved for second-line chronic lymphocytic leukemia (CLL) in 2014 by Janssen Biotech Inc. and Pharmacyclics Inc. based on overall response rate from a phase Ib/II study and then, later that year, with data from the phase III Resonate study where Imbruvica improved progression-free survival and overall survival compared to Arzerra (ofatumumab, Novartis AG).
Read More

Zymeworks, Beigene hook up (x2) in $1B-plus alliance

Nov. 28, 2018
By Brian Orelli
Beigene Ltd. clearly liked what it saw in the bispecific antibody platform being developed by Zymeworks Inc. The Beijing-based company is hooking up with Zymeworks in a pair of deals that could end up grossing Zymeworks more than $1 billion.
Read More

Biotech products surge thanks to big pharma spending

Nov. 20, 2018
By Brian Orelli
Biological drugs – monoclonal antibodies, peptides, recombinant proteins and the like – now account for more than 30 percent of all FDA approvals, according to a new study from the Tufts Center for the Study of Drug Development.
Read More

Biotech products surge thanks to big pharma spending

Nov. 19, 2018
By Brian Orelli
Biological drugs – monoclonal antibodies, peptides, recombinant proteins and the like – now account for more than 30 percent of all FDA approvals according to a new study from the Tufts Center for the Study of Drug Development.
Read More

Growing connections between vascular system and dementia

Nov. 8, 2018
By Brian Orelli
View All Articles by Brian Orelli

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 25, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 25, 2025.
  • Blue injector pens

    Biocon wins first FDA interchangeable label of Novolog biosimilar

    BioWorld Asia
    The U.S. FDA on July 15 cleared Biocon Biologics Ltd.’s Kirsty (insulin aspart-xjhz) as the first and only interchangeable biosimilar product referencing Novo...
  • Brain and neural networks

    Proteomics finds surprise commonalities as well as differences in neurodegenerative diseases

    BioWorld
    The switch will be flicked today to make the world’s largest dementia-related proteomics dataset freely available to researchers, at the same time as members of...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 22, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe